8-K: MetaVia's DA-1726 Shows Promising Adipose Tissue Distribution

MetaVia Inc. announced preclinical findings for DA-1726, demonstrating broad tissue distribution with highest exposure in adipose tissue and prolonged retention, supporting its potential for once-weekly dosing.

Summary

• MetaVia Inc. has released results from a preclinical tissue distribution study for its drug candidate DA-1726.
• The study indicates that DA-1726-derived radioactivity is slowly absorbed and widely distributed throughout the body after subcutaneous administration.
• The highest tissue exposure was observed in adipose (fat) tissue.
• Tissue-to-plasma ratios increased over time, suggesting prolonged retention of the radioactivity in tissues relative to plasma.
• The greatest exposure outside the injection site was found in abdominal, subcutaneous, and brown fat, as well as the liver.
• Prolonged retention was observed through the 144-hour assessment, supporting the potential for once-weekly dosing.
• Minimal radioactivity was detected in the central nervous system, consistent with limited brain penetration typical of peptide-based therapies.
• These findings provide mechanistic support for previously observed clinical results, including a mean reduction in waist circumference of 9.8 cm after eight weeks in a Phase 1 study at the 48 mg dose.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, highlighting promising preclinical data that supports the therapeutic potential of DA-1726 for obesity and cardiometabolic diseases.

Positives

• Preclinical study demonstrates broad tissue distribution of DA-1726, with highest exposure in adipose tissue.
• Prolonged retention of DA-1726-derived radioactivity in tissues supports the potential for once-weekly dosing.
• Findings provide a biological rationale for observed clinical efficacy, such as significant waist circumference reduction in Phase 1 studies.
• Limited central nervous system penetration is consistent with favorable safety profiles for peptide-based therapies.
• DA-1726 is a novel GLP1R/GCGR dual agonist with potential for superior weight loss compared to selective GLP-1 agonists.
• Preclinical models showed DA-1726 achieved comparable weight reduction to tirzepatide while consuming more food and preserving lean body mass.
• Phase 1 study showed DA-1726 (32 mg dose) has best-in-class potential for weight loss, glucose control, and waist circumference reduction.

Negatives

• The study is preclinical, and results are not necessarily predictive of future clinical outcomes.
• The company has a history of net losses and relies on raising additional capital.
• The full impact of the license agreement with Dong-A ST Co. Ltd. on future financial results is subject to realization.

Risks

• Results from preclinical studies are not necessarily predictive of future clinical results.
• Many factors could cause actual future events to differ materially from forward-looking statements, including the company's history of net losses and need for additional capital.
• The company's ability to execute its commercial strategy and obtain regulatory approval is subject to various risks.
• Potential negative interactions between DA-1726 and other treatments.
• Risks associated with initiating and completing clinical trials on a timely basis and recruiting subjects.
• The effects of changes in applicable laws, regulations, or Nasdaq listing rules.

Future Outlook

The company anticipates reporting 16-week topline data from its ongoing dose-titration study in the fourth quarter of 2026, followed by 24-week topline results in the first quarter of 2027. These results will evaluate whether longer treatment can further enhance reductions in waist circumference, weight loss, and other cardiometabolic measures.

Management Comments

• "We believe these findings provide important mechanistic support for the differentiated profile we continue to observe with DA-1726," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia.
• "In our previously reported Phase 1 study, patients receiving the 48 mg dose of DA-1726 achieved a mean reduction in waist circumference of 9.8 cm after only eight weeks of treatment (Day 54)."
• "We believe the preferential distribution of DA-1726-derived radioactivity to adipose tissue observed in this preclinical study provides an important biological rationale that is consistent with these encouraging clinical findings."
• "In addition, the prolonged retention of DA-1726-derived radioactivity in tissues observed throughout the study may contribute to the sustained pharmacokinetic profile of DA-1726 and may also help explain the excellent tolerability profile observed across our clinical studies, to date."
• "Together, these findings further reinforce our confidence in the unique potential of DA-1726 as a next-generation obesity therapy."
• "As patients in our ongoing 24-week dose-titration study continue to receive extended treatment at their highest achieved dose levels, we look forward to evaluating whether longer treatment can further enhance reductions in waist circumference, weight loss and other important cardiometabolic measures."
• "We anticipate reporting 16-week topline data in the fourth quarter of this year, followed by 24-week topline results in the first quarter of 2027."

Industry Context

StockSavvy.ai notes that the focus on GLP1R/GCGR dual agonists for obesity and cardiometabolic diseases is a significant trend in the pharmaceutical industry. MetaVia's DA-1726, with its potential for superior efficacy and favorable tolerability, positions it within a competitive but rapidly growing market.

Comparison to Industry Standards

• In preclinical mouse models, DA-1726 showed improved weight loss compared to semaglutide (Wegovy).
• DA-1726 demonstrated similar weight reduction to tirzepatide (Zepbound) and survodutide in preclinical models, while consuming more food and preserving lean body mass.
• DA-1726 showed improved lipid-lowering effects compared to survodutide in preclinical models.
• In a Phase 1 MAD trial, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction, suggesting it may outperform existing therapies in these metrics.

Stakeholder Impact

• Shareholders may see increased confidence in the company's lead drug candidate, DA-1726, potentially impacting stock valuation.
• Patients suffering from obesity and cardiometabolic diseases may benefit from the development of a potentially differentiated and effective new therapy.
• The pharmaceutical industry and competitors will monitor the progress of DA-1726 as a potential next-generation obesity treatment.

Next Steps

• Evaluate whether longer treatment in the ongoing 24-week dose-titration study can further enhance reductions in waist circumference, weight loss, and other cardiometabolic measures.
• Report 16-week topline data from the ongoing dose-titration study in the fourth quarter of 2026.
• Report 24-week topline results from the ongoing dose-titration study in the first quarter of 2027.

Key Dates

Recommendation

The preclinical data is promising and supports the rationale for DA-1726's efficacy and dosing schedule. However, the company is still in the clinical stages, has a history of net losses, and relies on future capital raises. While positive, the results are not yet definitive clinical outcomes, warranting a 'hold' recommendation pending further clinical data.

Keywords

DA-1726, obesity, cardiometabolic diseases, tissue distribution, adipose tissue, GLP1R, GCGR, preclinical study